Phosphodiesterase sequence variants may predispose to prostate cancer.
暂无分享,去创建一个
J. Epstein | T. Apanasovich | F. Faucz | C. Stratakis | A. Horvath | D. Carraro | F. Soares | L. Leal | E. Szarek | Allison D. Manning | R. B. de Alexandre | Fabio Kardauke | L. F. Leal
[1] W. Chiu,et al. Extension of anisotropic effective medium theory to account for an arbitrary number of inclusion types , 2015 .
[2] N. Niikawa,et al. Heterozygous mutations in cyclic AMP phosphodiesterase-4D (PDE4D) and protein kinase A (PKA) provide new insights into the molecular pathology of acrodysostosis. , 2014, Cellular signalling.
[3] F. Faucz,et al. Clinical and molecular genetics of the phosphodiesterases (PDEs). , 2014, Endocrine reviews.
[4] Jana Marie Schwarz,et al. MutationTaster2: mutation prediction for the deep-sequencing age , 2014, Nature Methods.
[5] J. Zhang,et al. Etazolate abrogates the lipopolysaccharide (LPS)-induced downregulation of the cAMP/pCREB/BDNF signaling, neuroinflammatory response and depressive-like behavior in mice , 2014, Neuroscience.
[6] D. Carraro,et al. Biobanking practice: RNA storage at low concentration affects integrity. , 2014, Biopreservation and biobanking.
[7] G. Jenster,et al. The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells , 2014, British Journal of Cancer.
[8] Klodiana Kolomitro,et al. Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer , 2013, World Journal of Urology.
[9] K. Sugihara,et al. 67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis. , 2013, The Journal of clinical investigation.
[10] T. Murata,et al. Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells , 2013, Oncology reports.
[11] K. Scott Coffield,et al. Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis. , 2013, Asian journal of andrology.
[12] Hong Wang,et al. Cancer therapy combination: green tea and a phosphodiesterase 5 inhibitor? , 2013, The Journal of clinical investigation.
[13] M. Sudol,et al. Modularity and functional plasticity of scaffold proteins as p(l)acemakers in cell signaling. , 2012, Cellular signalling.
[14] J. Bertherat,et al. Phosphodiesterase 11A (PDE11A) gene defects in patients with acth-independent macronodular adrenal hyperplasia (AIMAH): functional variants may contribute to genetic susceptibility of bilateral adrenal tumors. , 2012, The Journal of clinical endocrinology and metabolism.
[15] F. Faucz,et al. Identification of novel genetic variants in phosphodiesterase 8B ( PDE8B ), a cAMP‐specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours , 2012, Clinical endocrinology.
[16] Kevin W Eliceiri,et al. NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.
[17] T. Uchiumi,et al. Downregulation of phosphodiesterase 4B (PDE4B) activates protein kinase A and contributes to the progression of prostate cancer , 2012, The Prostate.
[18] Jiang-feng Du,et al. Inhibitory Effects and Underlying Mechanism of 7-Hydroxyflavone Phosphate Ester in HeLa Cells , 2012, PloS one.
[19] Diogo F. C. Patrão,et al. The value of a tumor bank in the development of cancer research in Brazil: 13 years of experience at the a C camargo hospital. , 2012, Biopreservation and biobanking.
[20] F. Pagani,et al. An exon-specific U1 small nuclear RNA (snRNA) strategy to correct splicing defects , 2012, Human molecular genetics.
[21] C. Cheadle,et al. Activation of cyclic AMP signaling leads to different pathway alterations in lesions of the adrenal cortex caused by germline PRKAR1A defects versus those due to somatic GNAS mutations. , 2012, The Journal of clinical endocrinology and metabolism.
[22] Frank Schwede,et al. Activation of PDE10 and PDE11 Phosphodiesterases* , 2011, The Journal of Biological Chemistry.
[23] Claire Lugnier,et al. Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1. , 2011, Molecular nutrition & food research.
[24] T. L. Mazzuco,et al. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations. , 2011, The Journal of clinical endocrinology and metabolism.
[25] F. Faucz,et al. Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer. , 2010, The Journal of clinical endocrinology and metabolism.
[26] F. Faucz,et al. Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype. , 2011, The Journal of clinical endocrinology and metabolism.
[27] D. Merkle,et al. Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor. , 2011, Cellular signalling.
[28] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer , 2011, Nature Biotechnology.
[29] V. Bours,et al. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes , 2010, Clinical genetics.
[30] D. Altshuler,et al. A map of human genome variation from population-scale sequencing , 2010, Nature.
[31] S. Washington,et al. A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy , 2010, Drug design, development and therapy.
[32] H. Parkinson,et al. A global map of human gene expression , 2010, Nature Biotechnology.
[33] E. Remmers,et al. Mutations and polymorphisms in the gene encoding regulatory subunit type 1‐alpha of protein kinase A (PRKAR1A): an update , 2010, Human mutation.
[34] H. Klocker,et al. Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP‐dependent protein kinase A , 2010, International journal of cancer.
[35] Chunyu Wang. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia , 2010, Current opinion in urology.
[36] Wei Zhang,et al. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G , 2009, Molecular Cancer Therapeutics.
[37] D. Schadendorf,et al. cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca2+ homeostasis in melanoma cells , 2009, Cellular and Molecular Life Sciences.
[38] Mohammed T Ansari,et al. Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis , 2009, Annals of Internal Medicine.
[39] Y. Nakamura,et al. Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways , 2009, Oncogene.
[40] M. Greene,et al. Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors. , 2009, Cancer research.
[41] Yun Liu,et al. LS-SNP/PDB: annotated non-synonymous SNPs mapped to Protein Data Bank structures , 2009, Bioinform..
[42] G. Lin,et al. Lack of direct androgen regulation of PDE5 expression. , 2009, Biochemical and biophysical research communications.
[43] J. Maguire,et al. Solution Hybrid Selection with Ultra-long Oligonucleotides for Massively Parallel Targeted Sequencing , 2009, Nature Biotechnology.
[44] N. Lawrentschuk,et al. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds , 2009, Current opinion in urology.
[45] D. Halpin. ABCD of the phosphodiesterase family: interaction and differential activity in COPD , 2008, International journal of chronic obstructive pulmonary disease.
[46] Christian von Mering,et al. STRING 8—a global view on proteins and their functional interactions in 630 organisms , 2008, Nucleic Acids Res..
[47] M. Pal,et al. Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. , 2008, Journal of medicinal chemistry.
[48] Alexandra M. E. Jones,et al. Broccoli Consumption Interacts with GSTM1 to Perturb Oncogenic Signalling Pathways in the Prostate , 2008, PloS one.
[49] J. Bertherat,et al. Phosphodiesterase 11A (PDE11A) and Genetic Predisposition to Adrenocortical Tumors , 2008, Clinical Cancer Research.
[50] I. Bossis,et al. Phosphodiesterase 11A Expression in the Adrenal Cortex, Primary Pigmented Nodular Adrenocortical Disease, and other Corticotropin-independent Lesions , 2008, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[51] E. Remmers,et al. Large Deletions of the PRKAR1A Gene in Carney Complex , 2008, Clinical Cancer Research.
[52] D. Burstein,et al. Large-scale comparative analysis of splicing signals and their corresponding splicing factors in eukaryotes. , 2007, Genome research.
[53] Li Ma,et al. Mitogen-activated Protein Kinase p38 Regulates the Wnt/Cyclic GMP/Ca2+ Non-canonical Pathway* , 2007, Journal of Biological Chemistry.
[54] Lise Getoor,et al. SplicePort—An interactive splice-site analysis tool , 2007, Nucleic Acids Res..
[55] P. Kochunov,et al. Akt/cAMP-Responsive Element Binding Protein/Cyclin D1 Network: A Novel Target for Prostate Cancer Inhibition in Transgenic Adenocarcinoma of Mouse Prostate Model Mediated by Nexrutine, a Phellodendron Amurense Bark Extract , 2007, Clinical Cancer Research.
[56] W. Sessa,et al. The phosphodiesterase 5 inhibitor sildenafil stimulates angiogenesis through a protein kinase G/MAPK pathway , 2007, Journal of cellular physiology.
[57] P. Gregersen,et al. Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population. , 2006, Cancer research.
[58] P. Sandner,et al. Pre‐clinical evidence for the use of phosphodiesterase‐5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms , 2006, BJU international.
[59] I. Bossis,et al. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia , 2006, Nature Genetics.
[60] H. Tillmanns,et al. Role of cGMP in Sildenafil-Induced Activation of Endothelial Ca(2+)-Activated K(+) Channels , 2006, Journal of cardiovascular pharmacology.
[61] Antonio Marín,et al. Characterization and prediction of alternative splice sites. , 2006, Gene.
[62] C. Stratakis,et al. Serial analysis of gene expression in adrenocortical hyperplasia caused by a germline PRKAR1A mutation. , 2006, The Journal of clinical endocrinology and metabolism.
[63] D. Campbell,et al. Phosphodiesterase 3A binds to 14-3-3 proteins in response to PMA-induced phosphorylation of Ser428. , 2005, The Biochemical journal.
[64] G. Morelli,et al. Inhibition of phosphodiesterase 11 (PDE11) impacts on sperm quality , 2005, International Journal of Impotence Research.
[65] R. Weiss,et al. Regulation of cyclic nucleotides in the urinary tract. , 2005, Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi.
[66] B. Zhu,et al. Suppression of cyclic GMP‐specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells , 2005, Journal of cellular biochemistry.
[67] Hsien-yu Wang,et al. PDE6 is an effector for the Wnt/Ca2+/cGMP-signalling pathway in development. , 2004, Biochemical Society transactions.
[68] R. Cote. Characteristics of Photoreceptor PDE (PDE6): similarities and differences to PDE5 , 2004, International Journal of Impotence Research.
[69] Francisco E. Baralle,et al. Genomic variants in exons and introns: identifying the splicing spoilers , 2004, Nature Reviews Genetics.
[70] J. Haynes,et al. Protein kinase G II-mediated proliferative effects in human cultured prostatic stromal cells. , 2004, Cellular signalling.
[71] H. Ke,et al. Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. , 2003, Structure.
[72] A. Sahu,et al. A phosphatidylinositol 3-kinase–phosphodiesterase 3B–cyclic AMP pathway in hypothalamic action of leptin on feeding , 2002, Nature Neuroscience.
[73] G. Baillie,et al. Sub‐family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP‐specific phosphodiesterases , 2000, British journal of pharmacology.
[74] G. Baillie,et al. ERK2 Mitogen-activated Protein Kinase Binding, Phosphorylation, and Regulation of the PDE4D cAMP-specific Phosphodiesterases , 2000, The Journal of Biological Chemistry.
[75] M. Fidock,et al. Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. , 2000, Biochemical and biophysical research communications.
[76] J. Beavo,et al. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[77] J. Beavo,et al. Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[78] K. Fujishige,et al. Cloning and Characterization of a Novel Human Phosphodiesterase That Hydrolyzes Both cAMP and cGMP (PDE10A)* , 1999, The Journal of Biological Chemistry.
[79] H. Granger,et al. Protein Kinase G Mediates Vascular Endothelial Growth Factor-induced Raf-1 Activation and Proliferation in Human Endothelial Cells* , 1998, The Journal of Biological Chemistry.
[80] M. Houslay,et al. cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. , 1998, The Biochemical journal.
[81] David Haussler,et al. Improved splice site detection in Genie , 1997, RECOMB '97.
[82] Peter G. Korning,et al. Splice Site Prediction in Arabidopsis Thaliana Pre-mRNA by Combining Local and Global Sequence Information , 1996 .
[83] E. Arnold,et al. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. , 1994, The American journal of physiology.
[84] J. Persson,et al. Protein kinase A (PKA) pathway is functionally linked to androgen receptor (AR) in the progression of prostate cancer. , 2014, Urologic oncology.
[85] G. Jenster,et al. The cAMP phosphodiesterase-4 D 7 ( PDE 4 D 7 ) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells , 2014 .
[86] R. Ganapathi,et al. Pharmacogenomics: New paradigms for targeted therapy based on individual response to drugs. , 2014, Urologic oncology.
[87] Emily H Turner,et al. Targeted Capture and Massively Parallel Sequencing of Twelve Human Exomes , 2009, Nature.
[88] M. Saito,et al. Effects of phosphodiesterase-5 inhibitors on sperm parameters and fertilizing capacity. , 2008, Asian journal of andrology.
[89] E. Degerman,et al. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. , 2001, Progress in nucleic acid research and molecular biology.
[90] C. A. Thomas,et al. Molecular cloning. , 1977, Advances in pathobiology.